6533b86dfe1ef96bd12ca933
RESEARCH PRODUCT
TAM895755_Supplementary_material_CLN – Supplemental material for Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study
Vincenzo AdamoGiuseppina Rosaria Rita RicciardiDario GiuffridaGiuseppa ScandurraAntonio RussoLivio BlasiPietro SpadaroCarmelo IaconoHector J. Soto ParraAntonino SavarinoFrancesco FerraúFilippo ZerilliFrancesco VerderameAlfredo ButeraCarlo SantangeloVeronica FranchinaMichele Carusosubject
110203 Respiratory DiseasesFOS: Clinical medicine111702 Aged Health CareFOS: Health sciences111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified111299 Oncology and Carcinogenesis not elsewhere classifieddescription
Supplemental material, TAM895755_Supplementary_material_CLN for Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study by Vincenzo Adamo, Giuseppina Rosaria Rita Ricciardi, Dario Giuffrida, Giuseppa Scandurra, Antonio Russo, Livio Blasi, Pietro Spadaro, Carmelo Iacono, Hector J. Soto Parra, Antonino Savarino, Francesco Ferraú, Filippo Zerilli, Francesco Verderame, Alfredo Butera, Carlo Santangelo, Veronica Franchina and Michele Caruso in Therapeutic Advances in Medical Oncology
year | journal | country | edition | language |
---|---|---|---|---|
2019-01-01 |